Overall market sentiment has been down on Millendo Therapeutics Inc (MLND) stock lately. MLND receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With MLND Stock Today?
Millendo Therapeutics Inc (MLND) stock is lower by -2.96% while the S&P 500 has risen 1.04% as of 10:46 AM on Wednesday, Jan 6. MLND is down -$0.05 from the previous closing price of $1.69 on volume of 1,029,738 shares. Over the past year the S&P 500 is higher by 16.00% while MLND is down -77.00%. MLND lost -$2.41 per share in the over the last 12 months.
More About Millendo Therapeutics Inc
Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. The company is also developing nevanimibe, an ACAT1 inhibitor for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS).